Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunostart: Prephase Tafasitamab, Retifanlimab, and Rituximab (TRR), Followed by TRR With Standard Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma

NCT05455697 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT05455697
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05455697 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunostart: Prephase Tafasitamab, Retifanlimab, and Rituximab (TRR), Followed by TRR With Standard Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma
Lead sponsor
University of Washington
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
January 26, 2023
Completion date
January 7, 2027
Enrollment
33 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma, grade 3b follicular lymphoma, high grade b-cell lymphoma